586-06-1 Usage
Originator
Alupent, Boehringer Ingelheim ,W. Germany ,1961
Uses
Bronchodilator.
Manufacturing Process
In an initial operation, 3,5-diacetoxyacetophenone was reacted first with
bromine and then with isopropylamine to give 1-(3,5-dihydroxyphenyl)-2-
isopropylaminoethanone.
59 g of 1-(3,5-dihydroxy-phenyl)-2-isopropylaminoethanone (free base) were
dissolved in 590 cc of methanol, and the solution was hydrogenated in the
presence of about 80 g Raney nickel at room temperature and under a
pressure of 5 atm. Hydrogen absorption was terminated after a few minutes.
The catalyst was separated by vacuum filtration, and the filtrate, an ethanolic
solution of 1-(3,5-dihydroxyphenyl)-1-hydroxy-2-isopropylaminoethane, was
admixed with the calculated amount of an alcoholic 20% sulfuric acid solution.
A crystalline precipitate formed which was filtered off and washed with
alcohol. For purification, the product was dissolved in water and the solution
was filtered through iron-free charcoal.
Thereafter, the filtrate was evaporated to dryness in vacuo and the residue
was taken up in alcohol. The crystalline precipitate which separated out after
some standing was separated by vacuum filtration and washed with alcohol.
After recrystallization from 90% alcohol, 61 g (83.2% of theory) of 1-(3,5-
dihydroxyphenyl)-1-hydroxy-2-isopropylamino-ethane sulfate, MP 202° to
203°C, was obtained.
Therapeutic Function
Bronchodilator
Check Digit Verification of cas no
The CAS Registry Mumber 586-06-1 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,8 and 6 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 586-06:
(5*5)+(4*8)+(3*6)+(2*0)+(1*6)=81
81 % 10 = 1
So 586-06-1 is a valid CAS Registry Number.
InChI:InChI=1/C11H17NO3/c1-7(2)12-6-11(15)8-3-9(13)5-10(14)4-8/h3-5,7,11-15H,6H2,1-2H3
586-06-1Relevant articles and documents
Combined doses
-
, (2008/06/13)
The present invention discloses a method and a pharmaceutical dry powder combined dose for the prophylaxis or treatment of a respiratory disorder in a mammalian host by inhalation of a metered dry powder combined dose of finely divided dry medication powders. At least one dry powder medicament is selected from a first group of bronchodilating medicaments and at least one dry powder medicament from a second group of anti-inflammatory medicaments. A metered dry powder medicinal combined dose comprising separately metered deposits of medicinally suitable quantities of each of the selected medicaments is prepared, in which the sum of the metered deposits constitutes the metered quantities of powder of the combined dose and the medicinal combined dose is introduced into an adapted inhaler device for a generally simultaneous delivery of the medicinal combined dose during the course of a single inhalation by a user, such that the delivered medicinal combined dose is composed of a high proportion of mixed de-aggregated fine particles of the selected medicaments, whereby an desired therapeutic or treating effect to the user is achieved.